List of Figures
Figure 1: Schizophrenia, US, Innovation Trends in Product Approvals, 1987–2014 6
Figure 2: Schizophrenia, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006–2013 8
Figure 3: Schizophrenia, Global Market by Molecular Target and Molecule Type, 2018 19
Figure 4: Schizophrenia, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2018 20
Figure 5: Schizophrenia, Global, Pipeline by Stage of Development and Molecule Type, 2018 21
Figure 6: Schizophrenia, Global, Pipeline by Molecular Target and Stage of Development, 2018 22
Figure 7: Schizophrenia, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018 23
Figure 8: Schizophrenia, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target Class, 2018 25
Figure 9: Schizophrenia, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018 25
Figure 10: Schizophrenia, Global, All Pipeline Programs, 2018 (part 1) 26
Figure 11: Schizophrenia, Global, All Pipeline Programs, 2018 (part 2) 27
Figure 12: Schizophrenia, Global, All Pipeline Programs, 2018 (part 3) 28
Figure 13: Schizophrenia, Global, All Pipeline Programs, 2018 (part 4) 29
Figure 14: Schizophrenia, Global, All Pipeline Programs, 2018 (part 5) 29
Figure 15: Schizophrenia, Global, First-in-Class Molecular Target Matrix Assessment, 2018 32
Figure 16: Schizophrenia, Global, Industry-Wide Licensing Deals by Stage of Development, 2006–2014 47
Figure 17: Schizophrenia, Global, Industry-Wide Deals by Stage of Development, 2006–2014 48
Figure 18: Schizophrenia, Global Licensing Deals by Region, Value and Year 2006–2018 49
Figure 19: Schizophrenia, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006–2018 50
Figure 20: Schizophrenia, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006–2018 51
Figure 21: Schizophrenia, Global, Licensing Deals with Disclosed Deal Values, 2006–2018 52
Figure 22: Schizophrenia, Global, Co-development Deals by Region, Value and Year 2006–2018 53
Figure 23: Schizophrenia, Global, Number and Aggregate Deal Value of Co-development Deals By Stage of Development and Year, 2006–2018 54
Figure 24: Schizophrenia, Global, Number and Aggregate Deal Value of Co-development Deals by Molecular Target Class, 2006–2018 55
Figure 25: Schizophrenia, Global, Co-development Deals with Disclosed Deal Values, 2006–2018 55
Figure 26: Schizophrenia, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006–2018 56